title: Mutations of the apolipoprotein A5 gene with inherited hypertriglyceridaemia: review of the current literature.
abstract: Apoliporotein A5 (APOA5), a member of the apolipoprotein family, plays a key regulatory role in triglyceride (TG) metabolism. Even though the exact biochemical background of its mechanism is not yet fully understood, diseases associated with this particular gene highlighted its key role in the metabolism of triglycerides in humans. Naturally occurring functional variants of the gene and their natural major haplotypes are known to associate with moderately elevated triglyceride levels, and are also known to confer risk or protection for major polygenic diseases, like coronary heart disease, stroke, or metabolic syndrome. On the other hand, case reports and even robust resequencing studies verified APOA5 mutations as underlying genetic defects behind extreme hypertriglyceridemic phenotype. Soon after the recognition of the first cases, there were indications which suggest the existence of less frequent genetic variants which, in combination with the common allelic variants of the gene, can define haplotypes that are associated with substantial triglyceride level increase. In addition, it became evident, that there are rare mutations of the APOA5 gene which can be associated with specific complex phenotypes and different types of hyperlipoproteinemia, which includes extremely high triglyceride levels with multiple organ pathology. These rare mutations may cause inheritable hypertriglyceridemia, but they presented at a low frequency and could not be captured by standard genotyping array screenings. The identification of new mutations still relies on the direct sequencing of APOA5 gene of patients with hypertriglyceridemia with an unusual pattern, individually or in huge resequencing studies.
authors.affiliation: Department of Medical Genetics, University of Pécs, Pécs, Hungary. bela.melegh@aok.pte.hu
authors.forename: B I
authors.initials: BI
authors.lastname: Melegh
authors.forename: B
authors.initials: B
authors.lastname: Duga
authors.forename: K
authors.initials: K
authors.lastname: Sümegi
authors.forename: P
authors.initials: P
authors.lastname: Kisfali
authors.forename: A
authors.initials: A
authors.lastname: Maász
authors.forename: K
authors.initials: K
authors.lastname: Komlósi
authors.forename: K
authors.initials: K
authors.lastname: Hadzsiev
authors.forename: S
authors.initials: S
authors.lastname: Komoly
authors.forename: G
authors.initials: G
authors.lastname: Kosztolányi
authors.forename: B
authors.initials: B
authors.lastname: Melegh
mesh_terms: D000072040:Apolipoprotein A-V; D001054:Apolipoproteins A / Q000235:genetics* / Q000378:metabolism; D055106:Genome-Wide Association Study; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D015228:Hypertriglyceridemia / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D020641:Polymorphism, Single Nucleotide; D014280:Triglycerides / Q000378:metabolism
chemical_list: C437704:APOA5 protein, human; D000072040:Apolipoprotein A-V; D001054:Apolipoproteins A; D014280:Triglycerides